Niagen Bioscience has launched Niagen Plus, a clinician-directed telehealth platform enabling eligible U.S. patients to access a prescription-only Niagen At-Home Injection Kit.
The program guides patients through an online medical intake and consultation with a licensed provider; when prescribed, the complete kit is dispensed by a licensed 503A pharmacy and shipped directly to the patient’s door.
The Niagen At-Home Injection Kit is designed for subcutaneous administration and includes a sterile 500 mg vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, a mixing syringe and needle, alcohol prep pads, and step-by-step instructions accessible by QR code.
The compounded kit is manufactured under cGMP standards using pharmaceutical-grade components and follows clinician-directed 50 mg or 100 mg dosing protocols.
The company also cites a clinical safety trial in which the kit was generally considered safe and well tolerated, with no significant adverse effects reported at 50 mg/mL and 100 mg/mL dosages.
Niagen Bioscience describes the launch as its first direct-to-client access model and presents injectable administration as a route that may bypass gut metabolism and offer greater tissue availability. The company referenced broader market research projecting growth in the injectable and longevity sectors.
